Anticipating Key Studies and Pipeline Treatments in mCRC Landscape
The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Read More
Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis
Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
Read More
Considerations for Platinum-based Therapy
Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.
Read More
Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
Read More
Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
Read More
Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
Read More
Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment
Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.
Read More
Overview of Current mCRC Treatment Landscape
Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.
Read More
Dr. Paulson Discusses Unmet Needs in the Treatment of NETs
September 27th 2018Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses unmet needs in the treatment of patients with neuroendocrine tumors.
Read More
Dr. Paulson Discusses the Current Treatment for NETs
September 5th 2018Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses the current treatment of patients with neuroendocrine tumors.
Read More
Dr. Paulson on When to Consider Lutathera in Patients With NETs
August 21st 2018Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses when to consider using Lutathera (lutetium Lu 177 dotatate) in patients with neuroendocrine tumors (NETs).
Read More
Dr. Paulson on the Importance of Symptom Control
January 23rd 2018Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses the unmet need for symptom control in patients with gastrointestinal cancers.
Read More